Bradley Freilich
Overview
Explore the profile of Bradley Freilich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1186
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rinella M, Lieu H, Kowdley K, Goodman Z, Alkhouri N, Lawitz E, et al.
Hepatology
. 2023 Sep;
79(3):674-689.
PMID: 37732990
Background And Aims: Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with noncirrhotic NASH; however, its efficacy and safety in compensated cirrhosis is unknown....
2.
Harrison S, Ruane P, Freilich B, Neff G, Patil R, Behling C, et al.
JHEP Rep
. 2023 Jan;
5(1):100563.
PMID: 36644237
Background & Aims: Efruxifermin has shown clinical efficacy in patients with non-alcoholic steatohepatitis (NASH) and F1-F3 fibrosis. The primary objective of the BALANCED Cohort C was to assess the safety...
3.
Fouad Y, Palmer M, Chen M, Regev A, Banerjee R, Myers R, et al.
J Clin Transl Hepatol
. 2022 May;
10(2):374-382.
PMID: 35528969
Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects a third of the population and is a leading cause of liver-related death. Since no effective treatments exist, novel approaches to drug development...
4.
Harrison S, Abdelmalek M, Neff G, Gunn N, Guy C, Alkhouri N, et al.
Lancet Gastroenterol Hepatol
. 2022 Mar;
7(7):603-616.
PMID: 35325622
Background: Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, and injury, and is associated with an increased risk of liver transplantation and death. NASH affects more than 16 million...
5.
Newsome P, Palmer M, Freilich B, Sheikh M, Sheikh A, Sarles H, et al.
J Hepatol
. 2020 Apr;
73(2):231-240.
PMID: 32234329
Background & Aims: Volixibat is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT) that has been hypothesized to improve non-alcoholic steatohepatitis (NASH) by blocking bile acid reuptake and...
6.
Patel K, Harrison S, Elkhashab M, Trotter J, Herring R, Rojter S, et al.
Hepatology
. 2020 Mar;
72(1):58-71.
PMID: 32115759
Background And Aims: We evaluated the safety and efficacy of cilofexor (formerly GS-9674), a small-molecule nonsteroidal agonist of farnesoid X receptor, in patients with nonalcoholic steatohepatitis (NASH). Approach And Results:...
7.
Harrison S, Goodman Z, Jabbar A, Vemulapalli R, Younes Z, Freilich B, et al.
J Hepatol
. 2019 Dec;
72(5):816-827.
PMID: 31887369
Background & Aims: Non-alcoholic steatohepatitis (NASH) is characterized by hepatocyte steatosis, ballooning, and lobular inflammation which may lead to fibrosis. Lipotoxicity activates caspases, which cause apoptosis and inflammatory cytokine (IL-1β...
8.
Pockros P, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz E, et al.
Liver Int
. 2019 Aug;
39(11):2082-2093.
PMID: 31402538
Background & Aims: Nonalcoholic steatohepatitis (NASH) is a chronic and severe form of nonalcoholic fatty liver disease that can progress to cirrhosis and hepatocellular carcinoma and is a risk factor...
9.
El Dika I, Lim H, Yong W, Lin C, Yoon J, Modiano M, et al.
Oncologist
. 2019 Jan;
24(6):747-e218.
PMID: 30598500
Lessons Learned: TKM-080301 showed a favorable toxicity profile at the studied dose.TKM-080301 targeting PLK1 through small interfering RNA mechanism did not demonstrate improved overall survival in patients with advanced hepatocellular...
10.
Shiffman M, Freilich B, Vuppalanchi R, Watt K, Chan J, Spada A, et al.
Aliment Pharmacol Ther
. 2018 Nov;
49(1):64-73.
PMID: 30430605
Background: Lipotoxicity leading to excessive caspase-mediated apoptosis and inflammation is believed to drive liver damage in NAFLD. Emricasan is a pan-caspase inhibitor that decreased serum ALT and apoptotic and inflammatory...